- Home
- PCQ vs SNY Comparison
PCQ vs SNY Comparison
Compare PCQ & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCQ | SNY |
|---|---|---|
| Founded | 2001 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.8M | 119.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PCQ | SNY |
|---|---|---|
| Price | $8.82 | $49.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $61.50 |
| AVG Volume (30 Days) | 69.6K | ★ 2.2M |
| Earning Date | 01-01-0001 | 10-24-2025 |
| Dividend Yield | ★ 4.63% | 3.21% |
| EPS Growth | N/A | ★ 105.93 |
| EPS | N/A | ★ 8.67 |
| Revenue | N/A | ★ $53,890,648,839.00 |
| Revenue This Year | N/A | $2.37 |
| Revenue Next Year | N/A | $6.51 |
| P/E Ratio | ★ N/A | $11.32 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.19 | $44.62 |
| 52 Week High | $10.50 | $60.12 |
Technical Indicators
Market Signals| Indicator | PCQ | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 50.35 | 48.29 |
| Support Level | $8.69 | $49.14 |
| Resistance Level | $8.99 | $50.61 |
| Average True Range (ATR) | 0.09 | 0.76 |
| MACD | -0.01 | -0.18 |
| Stochastic Oscillator | 45.00 | 28.73 |
Price Performance
Historical ComparisonAbout PCQ PIMCO California Municipal Income Fund
PIMCO California Municipal Income Fund is a closed-end management investment company. It seeks to provide current income exempt from federal and California income tax. The fund makes investments in different sectors such as healthcare, property, education, Natural Gas, and others.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.